The Pharma Letter38m
Vicebio raises $100 million for next-gen respiratory virus vaccines
British biotech Vicebio has secured $100 million in a series B funding round to advance its next-generation vaccines against ...
The Pharma Letter1h
Merck gains Singapore approval for Winrevair
The Health Sciences Authority (HSA) of Singapore has approved Merck & Co’s Winrevair (sotatercept), for the treatment of ...
The Pharma Letter1h
Fosun Pharma secures full ownership of Fosun Kite with $27 million deal
Shanghai-based Fosun Pharmaceutical has acquired the remaining 50% stake in Fosun Kite Biotechnology from Kite Pharma for $27 ...
The Pharma Letter1h
Teva reports positive Phase III data for schizophrenia treatment
Teva Pharmaceuticals has announced positive results from its Phase III SOLARIS trial of TEV-749, a long-acting injectable ...
The Pharma Letter1h
FTC sues PBMs over insulin drug prices
On Friday, the USA’s Federal Trade Commission (FTC) brought action against the three largest prescription drug benefit ...
The Pharma Letter1h
Sanofi’s Sarclisa gains third FDA approval
The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients ...